Literature DB >> 32129133

Bayesian Semi-parametric Design (BSD) for adaptive dose-finding with multiple strata.

Mo Li1, Rachael Liu2, Jianchang Lin2, Veronica Bunn2, Hongyu Zhao1.   

Abstract

In the era of precision medicine, it is of increasing interest to consider multiple strata (e.g. indications, regions, or subgroups) within a single oncology dose-finding study when identifying the maximum tolerated dose (MTD). We propose two Bayesian semi-parametric designs (BSD) for dose-finding with multiple strata to allow for both adaptively dosing patients based on various toxicity profiles and efficient identification of the MTD for each stratum. We develop non-parametric priors based on the Dirichlet process to allow for a flexible prior distribution and negate the need for a pre-specified exchangeability parameter. The two BSD models are built under different prior beliefs of strata heterogeneity and allow for appropriate borrowing of information across similar strata. Simulation studies are performed to evaluate the BSD model performance by comparing it with existing methods, including the fully stratified, exchangeability, and exchangeability-non-exchangeability models. In general, our BSD models outperform the competing methods in correctly identifying the MTD for different strata and necessitate a smaller sample size to determine the MTD. The BSD models are robust to various heterogeneity assumptions and can be easily extended to other binary and time to event endpoints.

Entities:  

Keywords:  Adaptive designs; Bayesian Dose finding; Bayesian semi-parametric model; Dirichlet process; maximum tolerated dose; multiple strata

Mesh:

Substances:

Year:  2020        PMID: 32129133     DOI: 10.1080/10543406.2020.1730870

Source DB:  PubMed          Journal:  J Biopharm Stat        ISSN: 1054-3406            Impact factor:   1.051


  3 in total

1.  Quantitative Translation in Immuno-Oncology Research and Development.

Authors:  Dean Bottino; Rachael Liu; Hojjat Bazzazi; Karthik Venkatakrishnan
Journal:  Clin Pharmacol Ther       Date:  2020-07-09       Impact factor: 6.875

Review 2.  Machine Learning and Artificial Intelligence in Pharmaceutical Research and Development: a Review.

Authors:  Sheela Kolluri; Jianchang Lin; Rachael Liu; Yanwei Zhang; Wenwen Zhang
Journal:  AAPS J       Date:  2022-01-04       Impact factor: 3.603

Review 3.  Practical Considerations and Recommendations for Master Protocol Framework: Basket, Umbrella and Platform Trials.

Authors:  Chengxing Cindy Lu; Xiaoyun Nicole Li; Kristine Broglio; Paul Bycott; Qi Jiang; Xiaoming Li; Anna McGlothlin; Hong Tian; Jingjing Ye
Journal:  Ther Innov Regul Sci       Date:  2021-06-23       Impact factor: 1.778

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.